shutterstock_1670805733.jpg

Proposed Acquisition of ResApp Health by Pfizer Australia Holdings Pty Limited, a wholly-owned subsidiary of Pfizer Inc, for $0.208 cash per share by scheme of arrangement.

Your Vote is Important

Your Directors unanimously recommend that you vote in favour of the Scheme, in the absence of a Superior Proposal and subject to the Independent Expert continuing to conclude that the Scheme is in the best interests of ResApp Health Shareholders.

 

The Independent Expert has concluded that the Scheme is in your best interests, in the absence of a superior proposal.

Contact Us

If you have any questions about the scheme, please contact the ResApp Health shareholder information line 1300 620 649 (within Australia) or +61 3 9415 4326 (outside Australia), Monday to Friday between 8:30am and 5:00pm (AEST).